Exploration of Causal and Correlational Modelling in Cancer : Glioblastoma Case Study

Total Page:16

File Type:pdf, Size:1020Kb

Exploration of Causal and Correlational Modelling in Cancer : Glioblastoma Case Study EXPLORATION OF CAUSAL AND CORRELATIONAL MODELLING IN CANCER : GLIOBLASTOMA CASE STUDY by SOMPOP SAENGPHUENG Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Dr. Sree N. Sreenath Department of Electrical Engineering & Computer Science CASE WESTERN RESERVE UNIVERSITY May 2015 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of SOMPOP SAENGPHUENG candidate for the Doctor of Philosophy degree * Dr. Sree N. Sreenath Dissertation Advisor Professor, Dr. James W. Jacobberger Professor, Dr. Mihajlo Mesarovic Professor, Dr. Vira Chankong Associate Professor, Dr. Evren Cavusoglu Assistant Professor, July 8th, 2014 *We also certify that written approval has been obtained for any proprietary material contained therein. Table of Contents Table of Contents ............................. iii List of Tables ............................... vii List of Figures ............................... viii Acknowledgement ............................. x Abstract .................................. xi 1 Introduction 1 1.1 Objective and Challenge ......................... 1 1.2 Biological Problem ............................ 4 1.3 Hallmark of Cancer and Angiogenesis .................. 7 1.4 Cause and Correlation of Angiogenesis in Glioblastoma ........ 8 1.5 Computer-aid analysis of causal structure ................ 9 1.6 Glioblastoma ............................... 9 1.7 Summary ................................. 9 2 Background 11 2.1 Glioblastoma or Glioblastoma multiforme (GBM) ........... 11 2.1.1 Glioblastoma ........................... 11 2.1.2 Causes of glioblastoma ...................... 12 2.1.3 Treatment ............................. 12 2.1.4 Glioblastoma, angiogenesis, and VEGF ............. 14 iii 2.1.5 Activation of VEGF pathway in glioblastoma ......... 16 2.1.6 Influence of VEGF on glioblastoma microvasculature ..... 16 2.1.7 Summary of VEGF in glioblastoma ............... 17 2.2 Understanding Angiogenesis and the VEGF Ligand ......... 17 2.2.1 Angiogenesis is regulated by the VEGF ligand ......... 17 2.2.2 The VEGF ligand is continuously expressed .......... 18 2.2.3 VEGF expression during tumor development .......... 20 2.2.4 Strategies for inhibiting the VEGF pathway .......... 21 2.2.5 Extracellular targeting of the VEGF ligand ........... 22 2.2.6 Intracellular targeting of the VEGF receptor .......... 23 2.2.7 Inhibition of new and recurrent tumor vessel growth ...... 23 2.2.8 Regression of existing tumor vasculature ............ 23 2.2.9 Regrowth of tumor vasculature ................. 24 2.2.10 The rationale for continuing VEGF inhibition ......... 25 2.2.11 An evolving understanding of tumor biology .......... 25 2.3 Cancer stem cells ............................. 27 2.4 Observational Model ........................... 28 2.5 Causal Model ............................... 30 2.6 Translating from causal to statistical model .............. 32 2.7 d-separation ................................ 33 2.8 Summary ................................. 34 3 Model Selection : Glioblastoma model 35 3.1 Glioblastoma model ............................ 35 3.1.1 Glucose .............................. 38 3.1.2 Oxygen .............................. 39 3.1.3 Transforming Growth Factor alpha ............... 41 iv 3.1.4 Vascular Endothelial Growth Factor (VEGF) ......... 41 3.1.5 Fibronectin ............................ 43 3.2 Other published works of brain cancer, angiogenesis, and cancer cell . 47 3.3 Summary ................................. 47 4 Methodology 50 4.1 Translating from causal to statistical model .............. 50 4.2 Statistical control and physical control ................. 51 4.3 Path analysis and d-separation ...................... 53 4.3.1 d-separation test ......................... 55 4.3.2 Independence of d-separation statements ............ 56 4.3.3 Testing for probabilistic independence .............. 58 4.4 Structural Equation Modeling (SEM) .................. 59 4.4.1 Steps to perform SEM analysis ................. 59 4.4.2 Path analysis and maximum likelihood ............. 62 4.4.3 Nested models and multilevel model ............... 63 4.5 The causal expression of SEM ...................... 65 4.5.1 Assumptions and representations ................ 65 4.5.2 Causal assumptions in nonparametric models ......... 67 4.5.3 Intervention and causal effects .................. 68 4.6 Exploration, discovery and equivalents of causal graph ........ 70 4.6.1 Exploring hypothesis space .................... 70 4.6.2 The shadow cause revisited ................... 71 4.6.3 Obtaining the undirected dependency graph .......... 71 4.6.4 Hypothesis setting ........................ 73 4.6.5 Causal inference for brain cancer ................ 73 4.7 Analysis of randomized experiment through SEM ........... 74 v 4.8 Develop a randomized experiment to address causal issues ...... 75 4.9 Advantages, Disadvantages, and Limitation ............... 76 4.10 Summary ................................. 77 5 Results 78 5.1 Part 1: Glioblastoma without TKI treatment .............. 79 5.2 Part 2: Glioblastoma with TKI treatment ............... 86 5.3 Estimation of path coefficient ...................... 90 6 Conclusion 96 6.1 Interpretation of the result ........................ 96 6.2 Suggestion for future research ...................... 98 6.3 Contribution ................................ 98 6.4 Summary ................................. 98 Appendix A The first Appendix 100 A.1 SEM and causality ............................ 100 A.2 Search algorithms using TETRAD ................... 103 A.2.1 PC algorithm ........................... 103 A.2.2 FCI algorithm ........................... 106 A.2.3 SEM parametric models ..................... 106 A.2.4 SEM instantiated model ..................... 107 A.3 Multilevelness of Angiogenesis ...................... 108 Bibliography 109 vi List of Tables 2.1 The effects of the VEGF ligand ..................... 19 3.1 Initial values and parameter values ................... 42 3.2 Other published works of brain cancer ................. 47 4.1 A basis set for the DAG ......................... 57 5.1 Mean coefficient and fit statistics of models without TKI ....... 85 5.2 Mean coefficient and fit statistics of models with TKI ......... 91 vii List of Figures 2.1 VEGF is known to express throughout the tumor life cycle ...... 20 2.2 Strategies for inhibiting the VEGF pathway .............. 21 2.3 Observational Relationships and Causal Relationships ......... 28 2.4 Statistical Model ............................. 29 2.5 A directed graph describing the causal relationships ......... 30 2.6 A directed graph used to illustrate the notion of d-separation .... 33 3.1 Multilevel phenotype switch functioning in the brain cancer ..... 37 3.2 Probability for endothelial tip cells migration .............. 49 4.1 The translation from a causal model to an observational model .... 50 4.2 Alternative causal model ......................... 52 4.3 A directed acyclic graph (DAG) involving six variables ........ 58 4.4 Nesting model: Model B is nested within A .............. 64 4.5 A simple SEM, and its associated diagrams ............... 66 4.6 The diagrams associated with model .................. 67 4.7 Path diagram vs Undirected graph ................... 72 5.1 Causal Model: Without TKI treatment ................. 80 5.2 Alternative Models: Without TKI treatment .............. 82 5.3 Causal Model: With TKI treatment ................... 86 viii 5.4 Alternative Models 1,2: With TKI treatment .............. 87 5.5 Alternative Models 3,4: With TKI treatment .............. 88 5.6 Estimation of path coefficient in causal model: With TKI treatment . 92 5.7 Implied correlation matrix of causal model: With TKI treatment ... 93 5.8 Estimation of path coefficient in alternative model: With TKI treatment 93 5.9 Implied correlation matrix of alternative model: With TKI treatment 94 A.1 SEM methodology depicted as an inference engine ........... 102 A.2 Causal Structure using PC algorithm .................. 104 ix ACKNOWLEDGEMENTS My dissertation would have not been finished without my professor, Dr. Mihajlo Mesarovic, who gives me guidance and inspires me in every possible way.He not only has given me knowledge, but he has also inspired and shaped my life. I have learned many things from him, and I am forever grateful for our relationship both inside and outside the classroom.It has been four years of being his visitor at home and it was the four years of enjoying conversation about my dissertation. I would like to thank you him for supporting me and devoting himself to my study since the beginning. I would like to thank you Dr. Sree N. Sreenath for his kind effort to support me and to provide an indispensable advice, information, and support on different aspects of my dissertation.Thank you for your patience with me over the last four years of my study. Your support was essential for my success here. Additionally, I would like to thank you Dr.Vira Chankhong who gives me an opportunity to pursuit my dream. I cannot imagine where am I going to be if he was not there at the first place.Without him I could not have a chance to see another successful steps of my life. Finally, I would like to thank you the committee,Dr. James W. Jacobberger and Dr. Evren Cavusoglu, whose work demonstrated to me that concern for cancer treat- ment requires another approach that can help solve the problems and it is required diversity of knowledge. Thank you. x Exploration of Causal and Correlational Modelling
Recommended publications
  • Anti-Angiogenic Drugs to Treat Human Disease: an Interview with Napoleone Ferrara
    Disease Models & Mechanisms 2, 324-325 (2009) doi:10.1242/dmm.002972 A MODEL FOR LIFE Published by The Company of Biologists 2009 Anti-angiogenic drugs to treat human disease: an interview with Napoleone Ferrara Napoleone Ferrara identified vascular endothelial growth factor (VEGF) as a major regulator of blood vessel development. The antibodies that he and his colleagues created to block VEGF action also block cancer growth. Here, he discusses the work that led to the development of the anti-cancer drug Avastin (bevacizumab), and discusses the role of basic science in clinical medicine. he formation of new blood But none of the molecules that were ini- vessels, or angiogenesis, is neces- tially characterized as potential angiogenic sary for the development of most factors seemed to be important as endoge- multicellular organisms. The new nous regulators. For example, basic fibrob- vessels allow for the perfusion of last growth factor (bFGF) was one of the Torgans and tissues, including those involved first factors to be purified and characterized in normal embryonic development, repro- as an angiogenic factor. It was extremely ductive function and skeletal growth. potent in several in vitro and in vivo DMM However, promoting blood vessel develop- systems, but then when researchers tried to ment also allows tumors to obtain neces- block bFGF function with antibodies, it had sary nutrients and survival factors and to little effect on tumor growth. Even the eliminate catabolic products. In 2004, Dr knockout of the gene for bFGF did not Ferrara’s work at Genentech led to the first result in any obvious defect in vascular de- Food and Drug Administration (FDA) ap- velopment, so clearly something was genic factor that regulated blood vessel for- proval of the anti-VEGF antibody, under the missing.
    [Show full text]
  • Prize Winner Announcement
    Contact: Seema Kumar Janssen Pharmaceutical Companies of Johnson & Johnson 908-218-6460 or [email protected] Diane Pressman Janssen Pharmaceutical Companies of Johnson & Johnson 908-927-6171 or [email protected] Frederik Wittock Janssen Pharmaceutical Companies of Johnson & Johnson +32 14 60 57 24 or [email protected] Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research Discovery Unlocked Key to Novel Anti-angiogenesis Therapies Washington, DC – June 28, 2011 – Johnson & Johnson today announced the winner of the 2011 Dr. Paul Janssen Award for Biomedical Research during the BIO International Convention (BIO) in Washington D.C. Napoleone Ferrara, M.D., is the seventh leading scientist to win the Award, which honors a scientist or team of scientists whose contributions have the potential to significantly improve the health and lives of people around the world. Dr. Ferrara was selected by an independent committee of eight renowned scientists, including Nobel Laureates, Lasker Prize winners, and others, for his research on angiogenesis, the process of new blood vessel formation that plays a key role in cancer proliferation and a number of other diseases. Dr. Ferrara’s discoveries opened the door to the development of a new class of therapeutics to combat a serious eye disorder and contributed to the development of new oncology therapeutics. “With the 2011 Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson recognizes Dr. Ferrara for the meaningful impact his discoveries have had on the lives of patients all over the world,” said Paul Stoffels, M.D., Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “Like Dr.
    [Show full text]
  • Progam Book Final(210 X 297Mm封面)
    GuangzhouGuangzhou InternationalInternational VascularVascular BiologyBiology ConferenceConference June 25, 2017 Organized by: Zhongshan Opthalmic Center, Sun Yat-sen University State Key Laboratory of Ophthalmology Welcome Acknowledgement Dear Colleagues and Friends, On behalf of the Chinese Vascular Biology Organization (CVBO), we are delighted to welcome you to our first International Vascular Biology Conference in Guangzhou, China. With the boost of economy, education and sciences in China in the past twenty years and a growing number of researchers returned to China from abroad, research in vascular biology in China is catching up and has made important contributions to the field, which promises a better progress in both basic and translational research in the future. The goals of this conference are to promote vascular biology research by establishing a platform for researchers and trainees to share and exchange cutting edge knowledge in vascular biology, and to boost communication, collaboration and education. We hereby welcome you to the beautiful city of Guangzhou, the “City of Flowers”, and hope that you will enjoy the great food and beautiful scenes of Guangzhou. We wish you a productive and enjoyable conference while staying in Guangzhou! Sincerely, Dr. Napoleone Ferrara Dr. Yizhi Liu Dr. Xuri Li 01 Guangzhou International Vascular Biology Conference 2017 The Zhongshan Ophthalmic Center (ZOC) The Zhongshan Ophthalmic Center (ZOC) is affiliated to Sun Yat-sen University in Guangzhou, the southern gateway to China. Since its inception in 1983, ZOC has been the largest eye care center in China. ZOC consists of three components: the Affiliated Ophthalmic Hospital, the Ophthalmic Research Institute, and the Department of Blindness Prevention.
    [Show full text]
  • Lasker Interactive Research Nom'18.Indd
    THE 2018 LASKER MEDICAL RESEARCH AWARDS Nomination Packet albert and mary lasker foundation November 1, 2017 Greetings: On behalf of the Albert and Mary Lasker Foundation, I invite you to submit a nomination for the 2018 Lasker Medical Research Awards. Since 1945, the Lasker Awards have recognized the contributions of scientists, physicians, and public citizens who have made major advances in the understanding, diagnosis, treatment, cure, and prevention of disease. The Medical Research Awards will be offered in three categories in 2018: Basic Research, Clinical Research, and Special Achievement. The Lasker Foundation seeks nominations of outstanding scientists; nominations of women and minorities are encouraged. Nominations that have been made in previous years are not automatically reconsidered. Please see the Nomination Requirements section of this booklet for instructions on updating and resubmitting a nomination. The Foundation accepts electronic submissions. For information on submitting an electronic nomination, please visit www.laskerfoundation.org. Lasker Awards often presage future recognition of the Nobel committee, and they have become known popularly as “America’s Nobels.” Eighty-seven Lasker laureates have received the Nobel Prize, including 40 in the last three decades. Additional information on the Awards Program and on Lasker laureates can be found on our website, www.laskerfoundation.org. A distinguished panel of jurors will select the scientists to be honored with Lasker Medical Research Awards. The 2018 Awards will
    [Show full text]
  • Michel Foucault Ronald C Kessler Graham Colditz Sigmund Freud
    ANK RESEARCHER ORGANIZATION H INDEX CITATIONS 1 Michel Foucault Collège de France 296 1026230 2 Ronald C Kessler Harvard University 289 392494 3 Graham Colditz Washington University in St Louis 288 316548 4 Sigmund Freud University of Vienna 284 552109 Brigham and Women's Hospital 5 284 332728 JoAnn E Manson Harvard Medical School 6 Shizuo Akira Osaka University 276 362588 Centre de Sociologie Européenne; 7 274 771039 Pierre Bourdieu Collège de France Massachusetts Institute of Technology 8 273 308874 Robert Langer MIT 9 Eric Lander Broad Institute Harvard MIT 272 454569 10 Bert Vogelstein Johns Hopkins University 270 410260 Brigham and Women's Hospital 11 267 363862 Eugene Braunwald Harvard Medical School Ecole Polytechnique Fédérale de 12 264 364838 Michael Graetzel Lausanne 13 Frank B Hu Harvard University 256 307111 14 Yi Hwa Liu Yale University 255 332019 15 M A Caligiuri City of Hope National Medical Center 253 345173 16 Gordon Guyatt McMaster University 252 284725 17 Salim Yusuf McMaster University 250 357419 18 Michael Karin University of California San Diego 250 273000 Yale University; Howard Hughes 19 244 221895 Richard A Flavell Medical Institute 20 T W Robbins University of Cambridge 239 180615 21 Zhong Lin Wang Georgia Institute of Technology 238 234085 22 Martín Heidegger Universität Freiburg 234 335652 23 Paul M Ridker Harvard Medical School 234 318801 24 Daniel Levy National Institutes of Health NIH 232 286694 25 Guido Kroemer INSERM 231 240372 26 Steven A Rosenberg National Institutes of Health NIH 231 224154 Max Planck
    [Show full text]
  • 2014 Annual Report Letter from the CHAIR and President
    LASKER FOUNDATION 2014 Annual Report LETTER FROM THE CHAIR AND PRESIDENT HE Lasker FOUNDATION is committed to improving health by inspiring support for medical research. We shine a light on outstanding advances that improve health and spread the word that The mission of the Albert and Mary Lasker Foundation T great science needs broad-based support in order to thrive. The Lasker Foundation believes that it is critical to educate people everywhere that is to improve health by accelerating support for MIKE OVERLOCK Chair investments in medical research yield valuable returns in the form of treatments for Albert and Mary Lasker Foundation debilitating disorders, new means of preventing diseases, and improved quality of life. medical research through recognition of research excellence, This is a very exciting time for the Lasker Foundation. The Lasker Awards continue to draw international attention to the powerful advances being made in research. We are spearheading a number of new educational initiatives that bring informa- public education and advocacy. tion about health and science to the public. And our growing advocacy work is more important than ever as NIH and other federal funding for research continues to lose purchasing power. The success of our work at the Lasker Foundation is buoyed by the support we CLAIRE PomeroY, MD, MBA President receive from you and the many others who are dedicated to our mission. Together Albert and Mary Lasker Foundation we can achieve our vision of a healthier world through medical research. Video: The Lasker Legacy http://vimeo.com/104527849 3 LASKER AWARDS PROGRAM Please join us in congratulating our Lasker Award winners.
    [Show full text]
  • Jennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., Win 2014 Dr
    Contact: Seema Kumar 732-524-2646 [email protected] Diane Pressman 908-927-6171 [email protected] Frederik Wittock +32 14 60 57 24 [email protected] Jennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., Win 2014 Dr. Paul Janssen Award for Biomedical Research SAN DIEGO – June 24, 2014 – Johnson & Johnson today named Dr. Jennifer Doudna of the the University of California, Berkeley, and Dr. Emmanuelle Charpentier, of the Hannover Medical School and Helmholtz Centre for Infection Research (HZI), Germany and The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Sweden, the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development. “Their discovery of this new DNA editing strategy is considered one of the most significant breakthroughs in molecular biology in the past decade,” said Paul Stoffels, MD, Chief Scientific Officer, Johnson & Johnson. “We are pleased to be able to recognize two researchers whose insights, persistence and collaboration have led to a significant leap in our understanding and ability to manipulate genetic processes. The work of Drs. Doudna and Charpentier has the potential to make a significant impact on human health, which is the very heart of Dr. Paul’s legacy, as well as our mission at Johnson & Johnson.” The Dr. Paul Janssen Award for Biomedical Research was created by Johnson & Johnson to honor the legacy of one of the most passionate, creative and productive scientists of the 20th century, Dr.
    [Show full text]
  • Nominations for Breakthrough Prizes in Life Sciences Now Open Online
    Nominations for Breakthrough Prizes in life sciences now open online 04 September 2013 | News | By BioSpectrum Bureau Nominations for Breakthrough Prizes in life sciences now open online The Breakthrough Prize in Life Sciences Foundation recently announced the opening of online nominations for Breakthrough Prizes for 2014. The rules and nomination form are made available in their official site. As per the rules, anyone can nominate a candidate online and all submissions must be completed by a third party. Nominations will be accepted through October 2, 2013. This year the foundation will award up to five prizes worth $3 million each, sponsored by Sergey Brin and Anne Wojcicki, Mark Zuckerberg and Priscilla Chan, and Yuri Milner. All prizes will be awarded for research aimed at curing deadly diseases and extending human life, with special attention to recent discoveries. One prize sponsored by Sergey Brin and Anne Wojcicki is aimed specifically at advancements in Parkinson's disease research. The 2014 prize winners will be chosen by the foundation's selection committee, comprised of prior recipients of the Breakthrough Prize in life sciences, including, Cornelia I. Bargmann, David Botstein, Lewis C. Cantley, Hans Clevers, Napoleone Ferrara, Titia de Lange, Eric S. Lander, Charles L. Sawyers, Bert Vogelstein, Robert A. Weinberg, and Shinya Yamanaka. "We all benefit from the brilliance and commitment of researchers at the frontiers of medical science. This is a chance to reward their achievements and support their future work. If you think someone deserves a Breakthrough Prize, you have the power to put them in the running," said Mr Art Levinson, Chairman of Apple Inc., Genentech, and The Breakthrough Prize in Life Sciences foundation.
    [Show full text]
  • 2018-01-03-Dr. Paul Janssen Award for Biomedical Research Issues
    Press Contacts: Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science Seema Kumar 908-405-1144 (M) [email protected] New Brunswick, N.J. – January 3, 2018 – Nominations are now being accepted for the 2018 Dr. Paul Janssen Award for Biomedical Research. This prestigious award Diane Pressman 908-927-6171 (O) celebrates today’s most dedicated researchers and champions of science whose [email protected] basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 28, 2018 at www.pauljanssenaward.com for consideration by an independent selection committee of world-renowned scientists. A $200,000 cash prize will be awarded to the scientist or group of scientists receiving the Award. The Dr. Paul Janssen Award for Biomedical Research honors Dr. Paul Janssen (1926-2003), one of the most productive pharmaceutical scientists of the 20th century, who was responsible for breakthrough treatments in key disease areas including pain management, psychiatry, infectious disease and gastroenterology. Janssen founded Janssen Pharmaceutica, N.V., now part of the Johnson & Johnson Family of Companies. “Behind every discovery that holds the promise for saving and improving lives are the scientists who pursue a vision and work tirelessly for many years to make it all possible,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “We are proud to honor the legacy of Dr. Paul by recognizing the outstanding researchers and champions of science who make a lasting impact on our world.” In 2017, the Dr.
    [Show full text]
  • Acknowledgment of Reviewers, 2009
    Proceedings of the National Academy ofPNAS Sciences of the United States of America www.pnas.org Acknowledgment of Reviewers, 2009 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2009. Their generous contribution is deeply appreciated. A R. Alison Adcock Schahram Akbarian Paul Allen Lauren Ancel Meyers Duur Aanen Lia Addadi Brian Akerley Phillip Allen Robin Anders Lucien Aarden John Adelman Joshua Akey Fred Allendorf Jens Andersen Ruben Abagayan Zach Adelman Anna Akhmanova Robert Aller Olaf Andersen Alejandro Aballay Sarah Ades Eduard Akhunov Thorsten Allers Richard Andersen Cory Abate-Shen Stuart B. Adler Huda Akil Stefano Allesina Robert Andersen Abul Abbas Ralph Adolphs Shizuo Akira Richard Alley Adam Anderson Jonathan Abbatt Markus Aebi Gustav Akk Mark Alliegro Daniel Anderson Patrick Abbot Ueli Aebi Mikael Akke David Allison David Anderson Geoffrey Abbott Peter Aerts Armen Akopian Jeremy Allison Deborah Anderson L. Abbott Markus Affolter David Alais John Allman Gary Anderson Larry Abbott Pavel Afonine Eric Alani Laura Almasy James Anderson Akio Abe Jeffrey Agar Balbino Alarcon Osborne Almeida John Anderson Stephen Abedon Bharat Aggarwal McEwan Alastair Grac¸a Almeida-Porada Kathryn Anderson Steffen Abel John Aggleton Mikko Alava Genevieve Almouzni Mark Anderson Eugene Agichtein Christopher Albanese Emad Alnemri Richard Anderson Ted Abel Xabier Agirrezabala Birgit Alber Costica Aloman Robert P. Anderson Asa Abeliovich Ariel Agmon Tom Alber Jose´ Alonso Timothy Anderson Birgit Abler Noe¨l Agne`s Mark Albers Carlos Alonso-Alvarez Inger Andersson Robert Abraham Vladimir Agranovich Matthew Albert Suzanne Alonzo Tommy Andersson Wickliffe Abraham Anurag Agrawal Kurt Albertine Carlos Alos-Ferrer Masami Ando Charles Abrams Arun Agrawal Susan Alberts Seth Alper Tadashi Andoh Peter Abrams Rajendra Agrawal Adriana Albini Margaret Altemus Jose Andrade, Jr.
    [Show full text]
  • Napoleone Ferrara Receives the 2010 Lasker~Debakey Clinical Award for Breakthroughs in Angiogenesis Research
    Napoleone Ferrara receives the 2010 Lasker~DeBakey Clinical Award for breakthroughs in angiogenesis research Ushma S. Neill J Clin Invest. 2010;120(10):3409-3412. https://doi.org/10.1172/JCI45092. News When Napoleone Ferrara was a medical student in Italy in the 1970s, he became interested in reproductive endocrinology. Although his training never specifically focused on angiogenesis, he is recognized today for shaping the field through the discovery of its core signaling molecule, VEGF, and for exploiting VEGF for the first successful clinical treatments of wet age-related macular degeneration (AMD) and cancer. On September 21, 2010, the Albert and Mary Lasker Foundation announced they will present Ferrara (Figure 1) with the 2010 Lasker~DeBakey Clinical Medical Research Award for his work on VEGF, which led to an effective therapy for neovascular AMD. Ferrara spoke with the JCI about his journey from discovery to treatment. Revving the endocrine engine Ferrara grew up in the shadow of the most active European volcano in Catania, Sicily. His father was a judge, and others in his family were in the legal profession, but his interest in the life sciences started even in high school: “To me,” Ferrara said, “it was much more interesting than the law.” He followed his passion to medical school, where he felt fortunate to land in the laboratory of Umberto Scapagnini. Ferrara noted that the University of Catania was much better known for its clinical focus than for its research, but “along came this dynamic young pharmacology professor who had trained for […] Find the latest version: https://jci.me/45092/pdf News Napoleone Ferrara receives the 2010 Lasker~DeBakey Clinical Award for breakthroughs in angiogenesis research When Napoleone Ferrara was a medi- knew best, and the endocrine cells that con- had the opportunity to go back to Italy, he cal student in Italy in the 1970s, he became trolled ovarian function were located in the said, “my heart wanted to stay in the United interested in reproductive endocrinology.
    [Show full text]
  • Acknowledgment of Reviewers, 2017
    Acknowledgment of Reviewers, 2017 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2017. Their generous contribution is deeply appreciated. A Katarzyna P. Adamala Hiroji Aiba Christine Alewine Jean Alric Hillie Aaldering Andrew Adamatzky Erez Lieberman Aiden Caroline M. Alexander Eben Alsberg Lauri A. Aaltonen Jozef Adamcik Allison E. Aiello R. Todd Alexander Manfred Alsheimer Duur K. Aanen Igor Adameyko Iannis Aifantis Alfredo Alexander-Katz Grégoire Altan-Bonnet Matthew L. Aardema Vic Adamowicz Christopher Aiken Anastassia N. Lee Altenberg Dirk G. A. L. Aarts David J. Adams Roger D. Aines Alexandrova Galit Alter Adam R. Abate David J. Adams Tracy D. Ainsworth Frank Alexis Orly Alter Cory Abate-Shen Jonathan Adams Edoardo Airoldi Emil Alexov Florian Altermatt Peter Abbamonte Michael E. Adams Jacqueline Michael Alfaro Marcus Altfeld Abul K. Abbas Patti Adank Aitkenhead-Peterson Hashim M. Al-Hashimi Dario C. Altieri Emmanuel A. Abbe R. Alison Adcock Slimane Ait-Si-Ali Asfar Ali Katye E. Altieri Shahal Abbo Zach N. Adelman Joanna Aizenberg Nageeb Ali Amnon Altman David H. Abbott Robert S. Adelstein Javier Aizpurua Robin R. Ali John D. Altman Geoffrey W. Abbott Andrew Adey Jaffer A. Ajani Saleem H. Ali Steven Altschuler Nicholas L. Abbott W. Neil Adger Caroline M. Ajo-Franklin Karen Alim Andrea Alu Omar Abdel-Wahab Jess F. Adkins Myles Akabas Michael T. Alkire Veronica A. Alvarez Ibrokhim Y. Ralph Adolphs Michael Akam Suvarna Alladi Javier Álvarez Abdurakhmonov Markus Aebi Omar S. Akbari Frédéric H.-T. Allain Arturo Alvarez-Buylla Ikuro Abe Yehuda Afek Erol Akcay David Alland David Amabilino Junichi Abe Hagit P.
    [Show full text]